TheEdgeResearch
Home / Stocks / BIO

Bio-Rad Laboratories, Inc. (BIO)

NYSE Healthcare Medical - Devices
$375.72 ▼ -0.18%
Market Cap
$10.11B
Sector
Healthcare
Industry
Medical - Devices
Beta
1.07
52-Wk Range
236.73-396.23
CEO
Norman D. Schwartz
Country
US
Currency
USD

Bio-Rad Laboratories, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Hercules, CA, US. The stock last traded at $375.72, down 0.18% on the session, giving a market capitalisation of $10.11B. On trailing twelve-month figures it carries a trailing P/E of 45.10, a net margin of 8.6%. Its beta of 1.07 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
45.10
Price / Sales
3.91
Price / Book
1.40
EV / EBITDA
20.20
Gross margin
51.9%
Operating margin
9.1%
Net margin
8.6%
Return on equity
Debt / equity
0.17
Current ratio
3.14
Dividend yield
0.0%
Payout ratio
22.0%
Company profile
Exchange
New York Stock Exchange
Employees
7,450
IPO date
1980-02-27
Headquarters
Hercules, CA, US
About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Comparable companies

Bio-Rad Laboratories, Inc. is most often compared with the following Healthcare names:

ALGNATRCRLDVAGMEDGRFSHQYHSICMASIPEN
More research on BIO
BIO technical analysis BIO TheEdge Score Compare against peers
Open full interactive analysis & DCF →